Medical device manufacturer VentiV Scientific has secured FDA clearance for its Mechanical Thrombectomy system, introducing a novel platform aimed at improving blood clot removal procedures across multiple medical specialties.
The VentiV Pulse platform addresses critical challenges in thrombectomy procedures, which are essential for treating conditions such as acute myocardial infarction, acute ischemic stroke, and peripheral arterial disease. Unlike traditional electric pump-based systems that can unexpectedly clog or remove significant blood volumes, the new system offers more precise control over thrombectomy force.
Dan Ryan, a board member of VentiV Scientific, highlighted the system's key innovations, emphasizing its ability to instantly start, stop, and modulate thrombectomy force while minimizing potential complications. The clearance includes 18 large-lumen catheter systems designed to address diverse clinical needs and potentially reduce procedural costs.
The technology represents a significant advancement in vascular intervention, providing clinicians with enhanced tools for managing complex blood clot removal scenarios. By offering more precise control and potentially reducing blood loss, the system could improve patient outcomes across various medical conditions involving blood clots.
This FDA clearance underscores the ongoing technological innovation in medical devices, particularly in the critical field of vascular intervention, where precise and minimally invasive procedures can significantly impact patient care and treatment efficacy.
